Upside – $CNTB +83% (Phase 2 COPD trial met its primary endpoint, reducing treatment failures by 81% and new moderate-to-severe exacerbations by 85%) – $NAUT +16% (no clear fresh catalyst identified; unusually large, liquid premarket move) – $CAPR +14% (new deramiocel analyses showed slower upper-limb decline in the HOPE-3 open-label extension and versus natural history) …
Read in context ›Stablecoin Development Corp Stock (SDEV)
Track Stablecoin Development Corp stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
SDEV
Stablecoin Development Corp
financial
At close
$0.99
â–¼ -0.26 (-20.80%)
Oct 14, 4:00 PM ET
After-hours
$1.02
â–² +0.03 (+3.03%)
Oct 14, 6:42 PM ET
Market Cap
$72.97M
P/E Ratio
0.1x
1Y Return
-79.17%
EPS (TTM)
-$7.43
Read the latest TheStreet Pro articles mentioning Stablecoin Development Corp, including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
0 articlesNo articles mentioning SDEV yet.
Daily Diary Mentions
1 mentionUpside, Downside Movers in the Morning